The popularity of Viagra initially fueled a period of growth for pharma, but recent changes present a complicated outlook for shareholders. Generic alternatives are eating into profits, and continued legal battles add more risk to the equation. While specific companies may still benefit from complementary products, the overall trend suggests a m… Read More